Vorapaxar
- Generic Name
- Vorapaxar
- Brand Names
- Zontivity
- Drug Type
- Small Molecule
- Chemical Formula
- C29H33FN2O4
- CAS Number
- 618385-01-6
- Unique Ingredient Identifier
- ZCE93644N2
- Background
Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.
- Indication
Vorapaxar is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). It is usually co-administered with acetylsalicylic acid (ASA) and/or clopidogrel, and should therefore be administered as an addition to these medications as it has not been studied alone.
- Associated Conditions
- Cardiovascular Events
Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)
- Conditions
- AtherosclerosisIschemiaMyocardial InfarctionCerebrovascular Accident
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 258
- Registration Number
- NCT00617123
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)
- Conditions
- AtherosclerosisMyocardial InfarctionMyocardial Ischemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12944
- Registration Number
- NCT00527943
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)
- Conditions
- AtherosclerosisIschemiaMyocardial InfarctionCerebrovascular AccidentPeripheral Arterial Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 26449
- Registration Number
- NCT00526474
Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573)
- Conditions
- Arterial Obstructive DiseasesCoronary Disease
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1030
- Registration Number
- NCT00132912
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.